Sanofi to acquire Vigil Neuroscience for $8.00/sh plus $2.00 CVR per share

Vigil Neuroscience, Inc.

Sanofi to pay $8.00/sh cash plus $2.00 CVR per share, contingent on first commercial sale of VG-3927 by Dec 31, 2035.
Vigil to return VGL101 to Amgen; deal conditioned on stockholder vote, HSR clearance, and no material adverse effect.
Supporting stockholders with ~16.2% voting power have agreed to vote for merger; board unanimously recommends.
Termination fees: $22.2M from Vigil for superior offer, $31.1M from Sanofi if antitrust clearance fails.

item 1.01item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.